Core and Group Health

One case involved a plan administrator that updated claim-processing systems for medical benefits but not for mental health benefits.

Decision support tools have helped, and now there's more focus on how AI-driven recommendation capabilities can build on that.

Pharmaceutical Strategies Group survey finds employers and health plans prioritizing cost control and cross-benefit management, with growing willingness to trade rebates for stronger utilization oversight amid rising complexity and CGT concerns.

Capital Blue Cross is partnering with the Mark Cuban Cost Plus Drug Co. to make lower‑cost biosimilar alternatives to Humira and Stelara available to commercial members.

The Health and Human Services secretary stuck with talking about health savings accounts.

The announcement comes as the House is considering a new, bipartisan Medicare Advantage plan prior authorization.